ClinicalTrials.gg
CompletedNCT01733121Updated Aug 10, 2017Results posted

NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia

A Phase 2 interventional study of NBI-98854 and NBI-98854 in Tardive Dyskinesia, sponsored by Neurocrine Biosciences. Completed at 22 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-08-10.

Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing valbenazine in Tardive Dyskinesia — 1 open to participants now, 1 under way, none of them phase 3. valbenazine · Tardive Dyskinesia.

Enrollment
7th of 14
102 · median 101
Started
2012
with 1 other
Phase 2
4 of 14
none open now
Registered
4th of 14
by date
Lead sponsor
11 of 14
Neurocrine Biosciences

Among the 14 studies testing valbenazine in Tardive Dyskinesia, this one is the 7th largest by enrollment, is one of 2 that started in 2012, is one of 4 in phase 2, and was the 4th registered.

Tardive Dyskinesia

62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.

Browse Tardive Dyskinesia studies →

Open to participants now

1 of the 14 studies testing valbenazine in Tardive Dyskinesia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About valbenazine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing valbenazine in Tardive Dyskinesia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 (titrated to a subject's optimal dose in the range of 25 to 75 mg) administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.

Read the detailed description

This is a Phase 2, randomized, double-blind, placebo-controlled, dose-titration study to evaluate the efficacy, safety, and tolerability of NBI-98854 (titrated to subject's optimal dose in the range of 25 to 75 mg) compared to placebo, administered once daily (q.d.) for a total of 6 weeks of treatment. Approximately 90 medically stable male and female subjects with one of the following clinical diagnoses will be enrolled: schizophrenia or schizoaffective disorder with neuroleptic-induced TD; mood disorder with neuroleptic-induced TD; or gastrointestinal disorder with metoclopramide-induced TD.

For subjects randomized to active treatment, the starting dose will be 25 mg NBI 98854, which may be escalated in increments of 25 mg every 2 weeks to a maximum of 75 mg to achieve an optimal dose of NBI-98854 for each subject

03

Conditions studied

  • Tardive Dyskinesia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have one of the following clinical diagnoses for at least 3 months prior to screening a) schizophrenia or schizoaffective disorder; b) mood disorder; or c) gastrointestinal disorder (e.g., gastroparesis, gastroesophageal reflux disease)
  • Have a clinical diagnosis of neuroleptic-induced tardive dyskinesia for at least 3 months prior to screening.
  • Be receiving a stable dose of antipsychotic medication for a minimum of 30 days before study start. Subjects who are not using antipsychotic medication must have stable psychiatric status.
  • Have the doses of concurrent medications and the conditions being treated be stable for a minimum of 30 days before study start and be expected to remain stable during the study.
  • Subjects of must agree to use hormonal or two forms of nonhormonal during the study.
  • Female subjects must not be pregnant.
  • Be in good general health and expected to complete the clinical study as designed.
  • Have a (BMI) of 18 to 38 kg/m2 (both inclusive).
  • Have a negative urine drug screen (negative for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids) at screening and study start, except for any subject receiving a stable dose of benzodiazepine.
  • Have a negative alcohol breath test at screening and study start.

Exclusion criteria

Exclusion Criteria:

  • Have an active unstable medical condition within 1 month (30 days) prior to screening.
  • Have a history of substance dependence or substance (drug) or alcohol abuse within the 3 months before study start(nicotine and caffeine dependence are not exclusionary).
  • Have a known history of neuroleptic malignant syndrome.
  • Have a significant risk of suicidal or violent behavior.
  • Receiving any excluded concomitant medication such as reserpine, metoclopramide, stimulants, or tetrabenazine.
  • Receiving medication for the treatment of tardive dyskinesia.
  • Have a positive antibody, (HIV-Ab), surface antigen (HBsAg), or virus (HCV) antibody result at screening or have a history of positive result.
  • Have received an drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study.
  • Have an allergy, , or intolerance to tetrabenazine.
  • Have had previous exposure with NBI-98854.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    NBI-98854

    Dose titration to determine a subject's optimal dose in the range of 25 to 75 mg NBI-98854. Dose titration is performed in increments of 25 mg. NBI-98854 administered as one (1) 25 mg capsule, two (2) 25 mg capsules, or one (1) 25 mg capsule and one (1) 50 mg capsule by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.

    Drug: NBI-98854

  • Placebo comparator
    Placebo

    Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6

    The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.

    Time frame: Baseline and Week 6

Secondary outcomes

  1. Clinical Global Impression - Global Improvement of TD (CGI-TD) at Week 6

    Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).

    Time frame: Week 6

  2. AIMS Dyskinesia Total Score Change From Baseline at Week 6

    The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.

    Time frame: Week 6

07

Results

Posted Aug 10, 2017

Participant flow

This study enrolled patients with schizophrenia or schizoaffective disorder with tardive dyskinesia (TD), a mood disorder with TD, or a GI disorder with TD from 29 centers in the United States and Puerto Rico. The last patient completed in December 2013.

Double-Blind Period (Week 0 to 6)
Participant flow — Double-Blind Period (Week 0 to 6)
MilestonePlaceboValbenazine
Started5151
Completed4446
Not completed75
Withdrew: Adverse event20
Withdrew: Non-compliance32
Withdrew: Withdrawal by subject13
Withdrew: Lost to follow-up10
Follow-Up Period (Week 6 to 8)
Participant flow — Follow-Up Period (Week 6 to 8)
MilestonePlaceboValbenazine
Started4446
Completed4446
Not completed00

Outcome measures

PrimaryAbnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6

The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · units on a scale
Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6
units on a scalePlaceboValbenazine
Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6-0.3 ± 1.1-3.4 ± 1.2
Statistical analysis
  • Placebo vs Valbenazine · ANCOVA · p = <.0001 · Mean difference (final values): -3.0 · 95% CI -4.5 to -1.6
SecondaryClinical Global Impression - Global Improvement of TD (CGI-TD) at Week 6

Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).

Time frame:
Week 6
Reported as:
Least squares mean · units on a scale
Clinical Global Impression - Global Improvement of TD (CGI-TD) at Week 6
units on a scalePlaceboValbenazine
Clinical Global Impression - Global Improvement of TD (CGI-TD) at Week 63.1 (2.5 to 3.6)2.2 (1.6 to 2.9)
Statistical analysis
  • Placebo vs Valbenazine · ANOVA · p = <0.0001 · Mean difference (final values): -0.8 · 95% CI -1.2 to -0.4
SecondaryAIMS Dyskinesia Total Score Change From Baseline at Week 6

The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.

Time frame:
Week 6
Reported as:
Least squares mean · units on a scale
AIMS Dyskinesia Total Score Change From Baseline at Week 6
units on a scalePlaceboNBI-98854
AIMS Dyskinesia Total Score Change From Baseline at Week 6-0.2 (-2.4 to 2.0)-2.6 (-4.9 to -0.3)
Statistical analysis
  • Placebo vs NBI-98854 · ANCOVA · p = 0.0005 · Mean difference (final values): -2.4 · 95% CI -3.7 to -1.1
SecondaryClinical Global Impression - Global Improvement of TD (CGI-TD) at Week 6

Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).

Time frame:
Week 6
Reported as:
Least squares mean · units on a scale
Clinical Global Impression - Global Improvement of TD (CGI-TD) at Week 6
units on a scalePlaceboValbenazine
Clinical Global Impression - Global Improvement of TD (CGI-TD) at Week 63.1 (2.5 to 3.6)2.2 (1.7 to 2.8)
Statistical analysis
  • Placebo vs Valbenazine · ANOVA · p = <.0001 · Mean difference (final values): -0.8 · 95% CI -1.2 to -0.5

Adverse events

Collected over up to 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/49 (2%)2/49 (4.1%)11/49 (22.4%)
Valbenazine0/51 (0%)0/51 (0%)16/51 (31.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboValbenazine
Urinary retentionRenal and urinary disorders1/490/51
ConvulsionNervous system disorders1/490/51
Myocardial infarctionCardiac disorders1/490/51
Most frequent other events
Most frequent other events
EventPlaceboValbenazine
FatigueGeneral disorders2/495/51
HeadacheNervous system disorders2/495/51
Decreased appetiteMetabolism and nutrition disorders0/494/51
ConstipationGastrointestinal disorders3/492/51
Urinary tract infectionInfections and infestations3/492/51
Dry mouthGastrointestinal disorders0/493/51
NauseaGastrointestinal disorders2/493/51
VomitingGastrointestinal disorders0/493/51
SomnolenceNervous system disorders1/493/51

Baseline characteristics

Safety analysis set (all randomized subjects who received at least one dose of study drug).

Age, Continuous
Age, Continuous(years)PlaceboValbenazineTotal
Mean55.6 (34 to 78)56.7 (32 to 78)56.2 (32 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboValbenazineTotal
Female222143
Male273057
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboValbenazineTotal
American Indian/Alaska native101
American Indian/Alaska native, Caucasian101
Black/African American161834
Caucasian303363
Other/mixed101
Body Mass Index
Body Mass Index(kg/m^2)PlaceboValbenazineTotal
Mean28.19 (18.0 to 38.3)29.02 (18.1 to 42.0)28.62 (18.0 to 42.0)
Disease Category
Disease Category(Participants)PlaceboValbenazineTotal
Schizophrenia or schizoaffective disorder302858
Mood disorder182038
Gastrointestinal disorder134
Age at TD Diagnosis
Age at TD Diagnosis(years)PlaceboValbenazineTotal
Mean49.5 (23 to 77)48.9 (25 to 70)49.2 (23 to 77)
BPRS Total Score
BPRS Total Score(units on a scale)PlaceboValbenazineTotal
Mean30.1 (19 to 49)30.1 (19 to 48)30.1 (19 to 49)
Baseline AIMS Total Dyskinesia Score
Baseline AIMS Total Dyskinesia Score(units on a scale)PlaceboValbenazineTotal
Mean7.9 ± 4.58.0 ± 3.58.0 ± 4.0
08

Study locations

22 sites
  • Costa Mesa, California 92626, United States
  • Fountain Valley, California 92708, United States
  • Oceanside, California 92056, United States
  • Englewood, Colorado 80113, United States
  • Boca Raton, Florida 33486, United States
  • Hialeah, Florida 33012, United States
  • Miami, Florida 33125, United States
  • Chicago, Illinois 60640, United States
  • Baltimore, Maryland 21287, United States
  • Farmington Hills, Michigan 48334, United States
  • Beachwood, Ohio 44122, United States
  • Middleburg Heights, Ohio 44130, United States
  • Conshohocken, Pennsylvania 19428, United States
  • Phoenixville, Pennsylvania 19460, United States
  • Bedford, Texas 76021, United States
  • DeSoto, Texas 75115, United States
  • Houston, Texas 77008, United States
  • Houston, Texas 77030, United States
  • Irving, Texas 75062, United States
  • San Antonio, Texas 78229, United States
  • Richland, Washington 99352, United States
  • Caguas, 00725, Puerto Rico
09

References and documents

Publications

  • Sajatovic M, Alexopoulos GS, Burke J, Farahmand K, Siegert S. The effects of valbenazine on tardive dyskinesia in older and younger patients. Int J Geriatr Psychiatry. 2020 Jan;35(1):69-79. doi: 10.1002/gps.5218. Epub 2019 Oct 31. PubMed 31617235 ↗
  • Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites. J Pharmacol Exp Ther. 2017 Jun;361(3):454-461. doi: 10.1124/jpet.116.239160. Epub 2017 Apr 12. PubMed 28404690 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 3 years 8 months after primary completion. A results delay was requested in Nov 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2012
First posted
Nov 26, 2012
Start
Dec 2012
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results delay requested
Nov 20, 2014
Results first posted
Aug 10, 2017
Last update
Aug 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01733121
Responsible party
Sponsor
First posted
Nov 26, 2012
Start date
Dec 2012
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Aug 10, 2017
Last update
Aug 10, 2017

Study contacts

Chris O'Brien, MD
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion